Background: APOA2 is a positional and biological candidate gene for type 2 diabetes at the chromosome 1q21-q24 susceptibility locus. The aim of this study was to examine if HapMap phase II tag SNPs in APOA2 are associated with type 2 diabetes and quantitative traits in French Caucasian subjects.
Background
The APOA2 gene is located at chromosome 1q23.3, within the 1-LOD support interval of several genomewide linkage scans for type 2 diabetes [1] [2] [3] . The peak of linkage in the French and Utah Caucasian genome-wide linkage scans was defined by the APOA2 intragenic microsatellite D1SAPO2 [1, 3] . APOA2 encodes the apolipoprotein (apo) A-II, the second most abundant protein of the high-density lipoprotein (HDL) particles [4, 5] .
Transgenic mice overexpressing human APOA2 on a standard chow diet displayed lipid profiles similar to that seen in human type 2 diabetes [6, 7] . Moreover, plasma human apoA-II levels were positively correlated with blood glucose levels and these animals displayed impaired glucose tolerance [7] . In the human HepG2 cell line and in rat primary hepatocytes, transcription of the human APOA2 transgene was upregulated by glucose in a HNF-4á-dependent fashion, whereas in streptozotocininduced diabetic rats Apoa2 mRNA levels were not affected [7] .
Overexpression of mouse Apoa2 contrastingly resulted in elevated levels of HDL and fasting blood glucose levels that were not significantly different from normal [8] [9] [10] . However, these mice appeared to be in a state of insulin resistance exhibiting two-fold raised plasma insulin levels, decreased triglyceride hydrolysis and increased fat deposition in adipose tissue, as well as delayed glucose clearance due to slower uptake in skeletal muscle [8] . Taken together, these findings point to a primary lipoprotein disturbance causing the development of several features of insulin resistance.
On the other hand, homozygous Apoa2 null-mice had HDL level reductions of 70%, as well as lower free fatty acid, glucose and insulin levels, suggesting they may be insulin hypersensitive [11] .
Previous genetic analysis of APOA2 in type 2 diabetes Elbein and colleagues tested four APOA2 variants for association with T2D by TDT in 698 family members and in a very small case-control cohort of 247 subjects [12] . None of the SNPs exhibited association with T2D in the casecontrol cohort, nor were any of the SNP alleles over-transmitted in the TDT analysis. Certain microsatellite alleles, however, indicated a trend for excess transmission to diabetic patients and marginal association with triglyceride levels, FFA and fasting glucose, as well as first phase insulin response and insulin deposition index in model analysis [12] .
Methods
Case-control subjects All subjects were of French Caucasian ancestry. Individuals identified by Sladek et al. [13] to lie outside the HapMap CEU ancestry cluster were excluded from the study. Type 2 diabetic case subjects were known diabetic patients receiving treatment for the condition. Normoglycaemic control subjects were selected to have a fasting blood glucose concentration <6.1 mM [14] . Case subjects were composed of: (i) 372 probands from diabetic families [3] , recruited in Lille; and (ii) 1083 patients with a family history of T2D recruited at the Corbeil-Essonne Hospital. Control subjects were composed of: (i) 353 normoglycaemic parents from T2D families; (ii) 543 subjects from the SUVIMAX (Supplementation en Vitamines et Minéraux Antioxidant) prospective population-based cohort study [15] ; and (iii) 742 subjects selected from the DESIR (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort, a large prospective study of insulin resistance in French subjects [16] . Informed consent was obtained from all subjects and the study was approved by the local ethics committees.
Statistical power
The case-control cohort comprised 1,455 type 2 diabetic subjects (age, 60 ± 12 years; BMI, 29.0 ± 6.0 kg/m 2 ; male/ female, 56:44%) and 1,638 normoglycaemic subjects (age, 54 ± 13 years; BMI, 24.1 ± 3.3 kg/m 2 ; male/female, 43:57%). At α = 0.05, this sample size provided 91% power [17] to detect a type 2 diabetes susceptibility variant, assuming an allele frequency of 0.20, a disease prevalence of 0.1 and a heterozygote relative risk of 1.2 (multiplicative model).
APOA2 tag SNP selection
The genomic target region for tag SNP selection extended across the 3 kb NCBI36 APOA2 locus (chr1:159,458,001..159,461,000). A total of three HapMap phase II pairwise tagging SNPs (rs6413453, rs5085 and rs5082) were sufficient to tag the common variation across the APOA2 locus (HapMap Data Release 22/Apr07) with r 2 and minor allele frequency (MAF) thresholds of 0.9 and 0.05, respectively.
SNP genotyping
Genotyping was performed with the Sequenom MassAR-RAY iPLEX system [18] . SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using chi-squared analysis. Quality control: all genotyped SNPs exhibited a call rate >99% and a Hardy-Weinberg P > 0.05, with well defined genotype clusters. In total, 19 case and 42 control subjects (1.97% of the total sample size) consistently failed genotyping and were removed from further analysis.
Statistical analyses
To test for association of APOA2 SNPs with type 2 diabetes, chi-squared analysis of allele and genotype counts was performed. Pairwise SNP linkage disequilibrium (LD) values were calculated from the genotype data of the control cohort with Haploview (4.0) [19] . Quantitative anthropomorphic phenotypes, body mass index (BMI), weight and waist-hip ratio (WHR), as well as fasting serum levels of glucose, insulin, triacylglycerol (TG), total and high-density lipoprotein (HDL)-cholesterol, apolipoprotein A-I (APOA1) and apolipoprotein B (APOB), measured in 1,539 normoglycaemic subjects from the control cohort, were log transformed and adjusted for age, sex and BMI, as appropriate. SNPs were tested for association with adjusted quantitative traits using SPSS 15.0 with the ANOVA test under a codominant model. Quantitative trait association p-values are presented uncorrected for multiple testing. Combined analysis of association datasets was carried out by pooling of log-transformed odds ratios with the inverse variance method for the fixedeffects and random-effects models. The DIAGRAM [20] data included a sib-ship component from the DGI GWAS [21] ; however, due to uncertainties about controlling for the effects of the relatedness of part of the study sample, we excluded these subjects and obtained data solely for unrelated subjects from the authors (E. Zeggini, personal communication, 23/04/2008). Inter-study heterogeneity was assessed with Cochran's Q statistic and the I 2 metric [22] . These calculations were performed using R (2.5.1) statistical software [23] .
Results
None of the three genotyped APOA2 tag SNPs showed evidence for association (P < 0.05) with type 2 diabetes in this French Caucasian cohort (Table 1; genotype counts  see Additional file 1: Additional table 1 ). This finding is in agreement with the French GWAS [13] , as well as a recent meta-analysis [20] of the DGI [21] , FUSION [24] and WTCCC [25] genome-wide association studies.
Quantitative trait associations
The APOA2 promoter SNP rs5082 was marginally associated with total cholesterol levels (P = 0.026) and waist-tohip ratio (P = 0.029) ( Table 2) , and both associations exhibited a linear increase of the value of the quantitative phenotype from the common homozygote to the rare homozygote allele carriers ( Table 3 ). The intronic variant rs6413453 was marginally associated with weight (P = 0.049), but given the small number of homozygote carriers of the minor allele (n = 13), it is likely that this is a spurious result (Table 2) .
Linkage disequilibrium structure of the APOA2 genomic locus The structure of linkage disequilibrium across the three tag SNPs studied was consistent with HapMap phase II data. The levels of intermarker LD (r 2 ) were negligible for the APOA2 locus (Additional file 1: Additional table 2). Therefore, no haplotype analysis was performed for APOA2 variants.
Meta-analysis of APOA2 variants
Meta-analysis combining publicly available data with our current study confirmed in over 12,000 subjects that none of the APOA2 tag SNPs were associated with type 2 diabetes (Additional files 2, 3, 4) and there appeared to be no study heterogeneity (Cochran's Q: P > 0.72; I 2 = 0% for all variants). Consistent with the absence of inter-study heterogeneity the fixed and random effects models were identical for all three variants, therefore only the fixed effects are displayed.
Discussion
The APOA2 gene appeared to be a highly plausible candidate gene for type 2 diabetes susceptibility. In addition to defining the peak of linkage at chromosome 1q in French and Utah Caucasian families, APOA2 is the second most abundant lipoprotein component of HDL-cholesterol and has been implicated in the regulation of lipid metabolism and insulin sensitivity.
Three HapMap phase II tag SNPs suffice to cover the common variation spanning APOA2 and genotyping of these variants demonstrated no association with type 2 diabetes. However, we cannot rule out the possibilities that distal common variants or rare APOA2 variants may be associated with type 2 diabetes. The quantitative trait association for the APOA2 variant rs5082 with total cholesterol levels was consistent with the physiological role of apoA-II; however, the strength of the association was marginal, as were the remaining, weaker associations with other continuous traits.
Meta-analysis of our data with DIAGRAM [20] consortium data, which was a mixture of directly genotyped and imputed SNPs (Table 1) , corroborated our findings of no association with type 2 diabetes. It was also welcome to note that the data from imputed SNPs were in this context indistinguishable from that of the directly genotyped variants.
Conclusion
Using a case-control cohort of over 3,000 subjects, we tested HapMap phase II tag SNPs that capture the common variation spanning the APOA2 genomic locus for association with type 2 diabetes, but failed to find any evidence supporting a contribution of this locus to type 2 diabetes susceptibility. This finding was confirmed in a combined analysis of more than 12,000 subjects. 
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